Q2 2024 EPS Estimates for FibroGen, Inc. Raised by Analyst (NASDAQ:FGEN)

FibroGen, Inc. (NASDAQ:FGEN - Free Report) - Stock analysts at William Blair boosted their Q2 2024 earnings per share estimates for FibroGen in a research report issued to clients and investors on Tuesday, May 7th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.24) per share for the quarter, up from their previous estimate of ($0.30). William Blair has a "Market Perform" rating on the stock. The consensus estimate for FibroGen's current full-year earnings is ($1.09) per share. William Blair also issued estimates for FibroGen's Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.82) EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.15 EPS.

FibroGen (NASDAQ:FGEN - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.15). The business had revenue of $27.14 million for the quarter, compared to analyst estimates of $40.00 million.

FibroGen Stock Performance

NASDAQ:FGEN traded down $0.06 during trading on Friday, reaching $1.16. The company's stock had a trading volume of 1,864,137 shares, compared to its average volume of 2,703,364. The firm has a market cap of $115.39 million, a price-to-earnings ratio of -0.47 and a beta of 0.88. FibroGen has a 12 month low of $0.33 and a 12 month high of $19.47. The firm has a 50 day moving average of $1.66 and a 200-day moving average of $1.25.

Insider Buying and Selling

In other news, CEO Thane Wettig bought 50,000 shares of the stock in a transaction on Thursday, March 7th. The shares were purchased at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the completion of the purchase, the chief executive officer now directly owns 470,178 shares in the company, valued at approximately $898,039.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently bought and sold shares of FGEN. Fox Run Management L.L.C. bought a new stake in FibroGen during the third quarter valued at $37,000. Mackenzie Financial Corp raised its position in FibroGen by 112.6% in the 3rd quarter. Mackenzie Financial Corp now owns 51,490 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 27,275 shares during the period. Quantbot Technologies LP bought a new stake in FibroGen in the third quarter worth $45,000. SG Americas Securities LLC grew its stake in shares of FibroGen by 498.8% during the third quarter. SG Americas Securities LLC now owns 62,710 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 52,237 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of FibroGen in the 3rd quarter valued at about $94,000. Institutional investors own 72.71% of the company's stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.